Paradromics is conducting an ongoing clinical study on how BCI users shift from prompted words to language that's fully their own.

ENABLING NEUROTECHNOLOGY Paradromics builds brain-computer interface (BCI) technologies for seamless human-technology integration, designed to restore and enhance human capabilities. By capturing brain activity at the resolution of individual neurons, our high-data-rate platform creates a foundation for the most advanced BCI applications. With each new application, we will create human capabilities that transcend disabilities, and eventually, biology itself. THE MISSION Data-driven BCI-based technologies for brain health Our technology will help millions with unmet medical needs suffering from paralysis and movement disorders to chronic pain, addiction, depression and other mental health conditions. ABOUT Matt Angle Ph.D. (CEO) founded Paradromics to build a high-data-rate BCI platform capable of addressing critical unmet clinical needs. With early funding from the NIH and DARPA, the company developed its core neurotechnology and, by 2019, shifted focus to its first product: the Connexus® BCI. Connexus is designed to restore communication through text, synthesized speech, and computer control for people with severe motor impairments, including those caused by ALS, stroke, or spinal cord injury. Backed by two FDA Breakthrough Device Designations and a successful first-in-human recording in May 2025, Paradromics achieved its first human implantation of the Connexus BCI as part of the FDA-approved Connect-One study in June 2026, marking a major milestone toward delivering its first product to people living with severe motor impairment.

Founded 2015